Our allergy assets remain an underpinning of Immunomic Therapeutics’ success, and have enabled our pivot to focus on oncology.
In addition to our canine atopic dermatitis vaccine concept, our vaccines using ITI’s lysosomal targeting technology have already been tested in several clinical studies in both allergy and oncology.